2010s

The Oncology Children’s Foundation (now known as The Kids’ Cancer Project) allocates $3.8 million to the Childhood Cancer Cytoskeleton Consortium, or C4 Consortium. Comprising six early and mid-career   researchers  , the consortium was formed to develop new therapies for hard-to-treat and non-responsive relapsed cancers. 
The Oncology Children’s Foundation forms the Research Advisory Committee (RAC), an independent body made up of national and international leaders in the field, including researchers, clinicians, and industry experts. 
The RAC is tasked with reviewing and rating all grant submissions. It has allowed the Oncology Children’s Foundation (now The Kids’ Cancer Project) to ensure equitable funding nationwide, while funding projects with the best chance of improving the lives of kids with cancer. 
Childhood cancer five-year survival rates in Australia climb to roughly 83%.

The Oncology Children’s Foundation (now known as The Kids’ Cancer Project) announces funding for two CAR T-Cell and gene therapy programs. The world’s first clinical trials of CAR T-Cell therapy for relapsed patients of Acute Lymphoblastic Leukaemia begin a year later.

The Oncology Children’s Foundation formally changes its name to The Kids’ Cancer Project.

The Kids’ Cancer Project announces a co-funding partnership with Cancer Australia (pdCCRS), with the aim of funding priority research areas for childhood cancer. The partnership sees 19 projects co-funded over nine years, totalling $3.1million.
Co-funding becomes commonplace for The Kids’ Cancer Project in the years that follow, as it allows the dollar to go further, allowing the charity to invest in additional projects.

Australia’s first CAR-T trial for paediatric leukaemia begins at the Royal Children’s Hospital, Melbourne. CAR-T cells are genetically modified T cells, designed to recognise and attack cancer cells by binding to a leukaemia cell and activating its immune response, eventually destroying the cancer cell.
Meanwhile, the Zero Childhood Cancer (ZERO) Program is launched in Australia to develop precision medicine approaches for high-risk childhood cancers. Trials begin a year later, made possible by an initial investment of $200,000 from The Kids’ Cancer Project, which allowed ZERO to demonstrate its capabilities to larger funding bodies.

The Kids’ Cancer Project establishes its formal partnership with ANZCHOG. The partnership was formed to provide support and infrastructure to facilitate the running of and access to clinical trials for Australian children with cancer.
Celebrating ten years of association in 2025, The Kids’ Cancer Project has contributed over $3.8 million, which has helped to support 15 clinical trials and approximately 375 participants. A national biobank is also created via the partnership.

The Federal Government establishes Australian Brain Cancer Mission,   with the goal of making transformative improvements to the quality and length of life of people with brain cancer, with the longer-term aim of defeating brain cancer. The Kids’ Cancer Project is named a Funding Partner, contributing $5.3 million over a ten-year period.

Artificial Intelligence makes waves in the Australian cancer research sector for the first time, with AI-driven drug discovery programs launched on the continent, identifying new potential childhood cancer therapies.